ESRP1 and/or ESRP2 further contribute to EMT by regulating the alternative splicing of FGFR2, Exo70, and CD44. Gain- and loss-of function studies showed that ESRP1 and 2 are required for the cell to modulate the expression of epithelial FGFR2 exon IIIb or the mesenchymal FGFR2 exon IIIc variant in various normal and cancer tissues [58]. This evidence concerns the gene CD44 and cancer.